Maude is a deal maker and company builder with over 17 years of business development corporate strategy, and cross functional business experience in public and private biotechnology, pharmaceutical and academic organizations. Prior to Seismic, she served as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company. She led key initiatives, including the negotiation of a $1B+ strategic partnership with BMS, expansion into targeted oncology, and the acquisition of Amplify Medicines. Previously, Maude was Executive Director, Business Development and Licensing at Merck & Co, leading oncology and immunology partnering in the Boston innovation hub. She served as Assistant Director, Business Development and Strategic Initiatives at Boston Children’s Hospital. She began her career at Xanthus Pharmaceuticals, where she had key roles in business development and program management of a Phase 3 drug candidate leading to its eventual FDA approval. Maude is a co-chair of the Boston Biobreak CBO forum. She is an investment advisory board member for the Brown University Biomedical Innovations to Impact Fund, and a mentor for Endless Frontier Labs. She holds an Honors Great Distinction BSc in Biochemistry from McGill University and a PhD from the Department of Medical Biophysics at the University of Toronto.